On 21 January 2021, Treatment Action Group and partners conducted a webinar on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and advanced HIV disease (AHD).

TB and viral hepatitis co-infections and advanced HIV disease (AHD) put the lives of people living with HIV at risk, and interventions to address these must be prioritized by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and reflected in its funding allocations. The development of FY2021 Country Operational Plans (COPs) provides a critical opportunity for advocates to ensure that the latest developments in preventing, diagnosing, and treating co-infections and AHD are implemented within PEPFAR programs.

The report — Tuberculosis Research Funding Trends, 2005–2019 — presents new data on 2019 funding for TB research and development and analyzes trends in investment since 2005.

Treatment Action Group (TAG) launches newly available TB chapters of its 2020 Pipeline Report.

On September 2nd and 3rd, Treatment Action Group (TAG) held a webinar series, “Demanding a Higher Standard of TB Care: New Tools, New Challenges, New Approaches to Improving TB Diagnosis and Treatment,” officially launching the two latest additions to TAG’s series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.

Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down

PLOS ONE publishes TAG’s rigorous, peer-reviewed calculation of investments in the development of this life-saving TB medicine.

Sustained and expanded financing is needed to safeguard TB research against COVID-19–related disruptions and improve global epidemic preparedness.

TAG and OTMeds call on Sanofi to reverse its efforts to patent two obvious combinations of two critical drugs to prevent TB: rifapentine and isoniazid.

Treatment Action Group launches two new TB Activist Guides: An Activist’s Guide to Tuberculosis Diagnostic Tools, and An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis.